» Articles » PMID: 11641310

Improvement in Blood Pressure, Arterial Stiffness and Wave Reflections with a Very-low-dose Perindopril/indapamide Combination in Hypertensive Patient: a Comparison with Atenolol

Overview
Journal Hypertension
Date 2001 Oct 20
PMID 11641310
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

International guidelines recommend that antihypertensive drug therapy should normalize not only diastolic (DBP) but also systolic blood pressure (SBP). Therapeutic trials based on cardiovascular mortality have recently shown that SBP reduction requires normalization of both large artery stiffness and wave reflections. The aim of the present study was to compare the antihypertensive effects of the very-low-dose combination indapamide (0.625 mg) and perindopril (2 mg) (Per/Ind) with the beta-blocking agent atenolol (50 mg) to determine whether Per/Ind decreases SBP and pulse pressure (PP) more than does atenolol and, if so, whether this decrease is predominantly due to reduction of aortic pulse wave velocity (PWV) (automatic measurements) and reduction of wave reflections (pulse wave analysis, applanation tonometry). In a double-blind randomized study, 471 patients with essential hypertension were followed for 12 months. For the same DBP reduction, Per/Ind decreased brachial SBP (-6.02 mm Hg; 95% confidence interval, -8.90 to -3.14) and PP (-5.57; 95% confidence interval, -7.70 to -3.44) significantly more than did atenolol. This difference was significantly more pronounced for the carotid artery than for the brachial artery. Whereas the 2 antihypertensive agents decreased PWV to a similar degree, only Per/Ind significantly attenuated carotid wave reflections, resulting in a selective decrease in SBP and PP. The very-low-dose combination Per/Ind normalizes SBP, PP, and arterial function to a significantly larger extent than does atenolol, a hemodynamic profile that is known to improve survival in hypertensive populations with high cardiovascular risk.

Citing Articles

Aortic Remodeling in Patients with Arterial Hypertension: Pathophysiological Mechanisms, Therapeutic Interventions and Preventive Strategies-A Position Paper from the Heart and Hypertension Working Group of the Italian Society of Hypertension.

Mancusi C, Basile C, Fucile I, Palombo C, Lembo M, Buso G High Blood Press Cardiovasc Prev. 2025; .

PMID: 40082374 DOI: 10.1007/s40292-025-00710-3.


Post-exercise differential response of central and brachial blood pressure in patients with coronary artery disease: A randomized crossover trial.

Maroco J, Angarten V, Pinto R, Santos V, Fernhall B, Santa-Clara H PLoS One. 2025; 20(2):e0317212.

PMID: 39982938 PMC: 11844900. DOI: 10.1371/journal.pone.0317212.


ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.

Sobhy M, Eletriby A, Ragy H, Kandil H, Saleh M, Farag N Cardiol Ther. 2024; 13(4):707-736.

PMID: 39455534 PMC: 11607301. DOI: 10.1007/s40119-024-00381-6.


Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis.

Faverio P, Maloberti A, Rebora P, Intravaia R, Tognola C, Toscani G High Blood Press Cardiovasc Prev. 2024; 31(3):289-297.

PMID: 38739257 PMC: 11161536. DOI: 10.1007/s40292-024-00638-0.


Estimation of central blood pressure waveform from femoral blood pressure waveform by blind sources separation.

Gbaoui L, Hoeschen C, Kaniusas E, Khatib S, Gretschel S, Wellnhofer E Front Cardiovasc Med. 2023; 10:1280899.

PMID: 38045918 PMC: 10690369. DOI: 10.3389/fcvm.2023.1280899.